Sort by
Previous Page Page 1 of 59 Next Page
  1. Research article

    Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer

    Hepatocellular carcinoma (HCC) is a major health problem worldwide with increasing incidence rates. As HCC traditionally occurs in chronically inflamed livers, this inflammation aids to drive oncogenesis and o...

    Zachary J. Brown, Bernd Heinrich, Seth M. Steinberg, Su Jong Yu and Tim F. Greten

    Journal for ImmunoTherapy of Cancer 2017 5:93

    Published on: 21 November 2017

  2. Research article

    A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

    Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of d...

    Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall and Craig L. Slingluff Jr

    Journal for ImmunoTherapy of Cancer 2017 5:92

    Published on: 21 November 2017

  3. Review

    Prospects for combined use of oncolytic viruses and CAR T-cells

    With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic optio...

    Adam Ajina and John Maher

    Journal for ImmunoTherapy of Cancer 2017 5:90

    Published on: 21 November 2017

  4. Research article

    Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

    Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit ...

    Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz and Wilson H. Miller Jr

    Journal for ImmunoTherapy of Cancer 2017 5:83

    Published on: 21 November 2017

  5. Review

    Biomarkers for immunotherapy in bladder cancer: a moving target

    Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for...

    David H. Aggen and Charles G. Drake

    Journal for ImmunoTherapy of Cancer 2017 5:94

    Published on: 21 November 2017

  6. Position article and guidelines

    Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a d...

    I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham III, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra…

    Journal for ImmunoTherapy of Cancer 2017 5:95

    Published on: 21 November 2017

  7. Research article

    Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response

    It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in ...

    Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim and Jing Zhou

    Journal for ImmunoTherapy of Cancer 2017 5:85

    Published on: 21 November 2017

  8. Case report

    Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?

    Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with cancer, and studies using immunotherapy have show...

    Gustavo dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes and Renata de Almeida Coudry

    Journal for ImmunoTherapy of Cancer 2017 5:84

    Published on: 21 November 2017

  9. Case report

    Smoldering myocarditis following immune checkpoint blockade

    Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of...

    Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi and Robert M. Conry

    Journal for ImmunoTherapy of Cancer 2017 5:91

    Published on: 21 November 2017

  10. Review

    The immune system in cancer metastasis: friend or foe?

    Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...

    Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

    Journal for ImmunoTherapy of Cancer 2017 5:79

    Published on: 17 October 2017

  11. Research article

    Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

    Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...

    Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm

    Journal for ImmunoTherapy of Cancer 2017 5:81

    Published on: 17 October 2017

  12. Review

    Immuno-thermal ablations – boosting the anticancer immune response

    The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...

    Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

    Journal for ImmunoTherapy of Cancer 2017 5:78

    Published on: 17 October 2017

  13. Research Article

    Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

    Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases tr...

    Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada and Kathryn Beal

    Journal for ImmunoTherapy of Cancer 2017 5:76

    Published on: 17 October 2017

  14. Research article

    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

    There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...

    Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana and Ulka Vaishampayan

    Journal for ImmunoTherapy of Cancer 2017 5:82

    Published on: 17 October 2017

  15. Erratum

    Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

    Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Journal for ImmunoTherapy of Cancer 2017 5:80

    Published on: 28 September 2017

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:68

  16. Research article

    High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

    Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...

    Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

    Journal for ImmunoTherapy of Cancer 2017 5:74

    Published on: 19 September 2017

  17. Research article

    Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

    Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...

    Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

    Journal for ImmunoTherapy of Cancer 2017 5:72

    Published on: 19 September 2017

  18. Meeting report

    Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

    Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...

    Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

    Journal for ImmunoTherapy of Cancer 2017 5:77

    Published on: 19 September 2017

  19. Research article

    Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

    Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in co...

    Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville

    Journal for ImmunoTherapy of Cancer 2017 5:70

    Published on: 19 September 2017

  20. Research article

    Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

    Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...

    Veronika Kremer, Marteen A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Journal for ImmunoTherapy of Cancer 2017 5:73

    Published on: 19 September 2017

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:88

  21. Research article

    Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

    Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in...

    Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher

    Journal for ImmunoTherapy of Cancer 2017 5:71

    Published on: 19 September 2017

  22. Case report

    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

    Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinu...

    Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal and David Jablons

    Journal for ImmunoTherapy of Cancer 2017 5:75

    Published on: 19 September 2017

Previous Page Page 1 of 59 Next Page
JITC logo